Of these participants, 36% experienced grade ≥ 3 thrombocytopenia and 16% experienced grade ≥ 3 neutropenia, resulting in a safety profile comparable with other HDAC inhibitors [79]. This evidence concerns the gene HDAC9 and Decreased total neutrophil count.